Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Primary Purpose
Hyperglycemia, Hyperlipidemia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Olanzapine
Ziprasidone
Sponsored by
About this trial
This is an interventional prevention trial for Hyperglycemia focused on measuring healthy, sedentary, men, acute effects of antipsychotic, blood sugar, insulin sensitivity
Eligibility Criteria
Inclusion Criteria:
- Males aged 18-45 years
- BMI approximately ≥ 25 and < 35
- insulin approximately ≥ 15 µU/ml or triglyceride approximately ≥ 130 mg/dl
Exclusion Criteria:
- Any DSM-IV Axis I diagnosis
- prisoners
- any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection)
- taking prescription medications
- non-sedentary lifestyle with > 3 hours of exercise per week
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
olanzapine
ziprasidone
saline
Arm Description
olanzapine injection in healthy control
ziprasidone injection in healthy control
saline injection in healthy control
Outcomes
Primary Outcome Measures
Whole Body Insulin Sensitivity
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates (mg/kg/min).
Hepatic Insulin Sensitivity
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as hepatic glucose production (glucose rate of appearance [Ra]).
Peripheral Insulin Sensitivity
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as primarily muscle glucose utilization (glucose rate of disappearance [Rd]).
Adipose Tissue Insulin Sensitivity
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as free fatty acid release (glycerol rate of appearance [Ra]).
Secondary Outcome Measures
Full Information
NCT ID
NCT00910988
First Posted
February 3, 2009
Last Updated
June 20, 2018
Sponsor
Washington University School of Medicine
Collaborators
Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT00910988
Brief Title
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Official Title
A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
Pfizer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary Aim: To test the acute effects of olanzapine or ziprasidone administration, in comparison to placebo, on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates (mg/kg/min), hepatic glucose production (glucose rate of appearance [Ra]), primarily muscle glucose utilization (glucose rate of disappearance [Rd]), and adipose tissue related free fatty acid production (glycerol rate of appearance [Ra]).
We hypothesize that olanzapine, but not ziprasidone, will result in acute decreases in insulin sensitivity.
Secondary Aim: To test the acute effects of olanzapine or ziprasidone on insulin signaling pathways in antipsychotic naïve healthy young men.
We hypothesize that olanzapine, but not ziprasidone, will result in acute alterations in insulin signaling.
Detailed Description
See brief description
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperglycemia, Hyperlipidemia
Keywords
healthy, sedentary, men, acute effects of antipsychotic, blood sugar, insulin sensitivity
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
olanzapine
Arm Type
Active Comparator
Arm Description
olanzapine injection in healthy control
Arm Title
ziprasidone
Arm Type
Active Comparator
Arm Description
ziprasidone injection in healthy control
Arm Title
saline
Arm Type
Placebo Comparator
Arm Description
saline injection in healthy control
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Other Intervention Name(s)
Zyprexa
Intervention Description
olanzapine/Zyprexa
Intervention Type
Drug
Intervention Name(s)
Ziprasidone
Other Intervention Name(s)
Geodon
Intervention Description
ziprasidone/Geodon
Primary Outcome Measure Information:
Title
Whole Body Insulin Sensitivity
Description
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as whole-body dextrose infusion rates (mg/kg/min).
Time Frame
approximately 3 hours
Title
Hepatic Insulin Sensitivity
Description
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as hepatic glucose production (glucose rate of appearance [Ra]).
Time Frame
approximately 3 hours
Title
Peripheral Insulin Sensitivity
Description
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as primarily muscle glucose utilization (glucose rate of disappearance [Rd]).
Time Frame
approximately 3 hours
Title
Adipose Tissue Insulin Sensitivity
Description
To evaluate, using a within-subject placebo-controlled comparison, the acute effects of olanzapine or ziprasidone administration on insulin sensitivity in antipsychotic-naïve healthy young men, measured as free fatty acid release (glycerol rate of appearance [Ra]).
Time Frame
approximately 3 hours
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males aged 18-45 years
BMI approximately ≥ 25 and < 35
insulin approximately ≥ 15 µU/ml or triglyceride approximately ≥ 130 mg/dl
Exclusion Criteria:
Any DSM-IV Axis I diagnosis
prisoners
any serious medical disorder (i.e. metabolic diseases, type 1 or 2 diabetes mellitus, endocrine disease, coagulopathy, clinically significant anemia, acute infection)
taking prescription medications
non-sedentary lifestyle with > 3 hours of exercise per week
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John W Newcomer, MD
Organizational Affiliation
Washington University School of Medicine and Florida Atlantic University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ginger Nicol, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
We'll reach out to this number within 24 hrs